---
title: "RCKT.US (RCKT.US) — Related News"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/RCKT.US/news.md"
symbol: "RCKT.US"
name: "RCKT.US"
parent: "https://longbridge.com/en/quote/RCKT.US.md"
datetime: "2026-05-20T06:05:30.159Z"
locales:
  - [en](https://longbridge.com/en/quote/RCKT.US/news.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/RCKT.US/news.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/RCKT.US/news.md)
---

# RCKT.US (RCKT.US) — Related News

### [Balanced View on Rocket: Hold Rating Reaffirmed as Danon Trial Resumes Under Revised Protocol and Pipeline Progress Offsets Ongoing Safety and Execution Risks](https://longbridge.com/en/news/285866798.md)
*2026-05-11T01:45:16.000Z*
> TD Cowen analyst Tara Bancroft has reaffirmed a Hold rating on RCKT stock, citing a balance of clinical progress and ong

### [Rocket Pharmaceuticals (NASDAQ:RCKT) Announces Earnings Results](https://longbridge.com/en/news/285819778.md)
*2026-05-09T18:45:14.000Z*
> Rocket Pharmaceuticals (NASDAQ:RCKT) reported quarterly earnings of ($0.42) EPS, missing analysts' estimates of ($0.41) 

### [Rocket Pharma | 8-K: FY2026 Q1 Revenue: USD 0](https://longbridge.com/en/news/285621944.md)
*2026-05-07T21:15:55.000Z*
### [RCKT Q1'26 Earnings: revenue estimate is 0 USD](https://longbridge.com/en/news/285060856.md)
*2026-05-04T11:00:28.000Z*
> RCKT (Rocket Pharmaceuticals, Inc.) is set to announce its Q1'26 results on May 11, time not specified. The earnings are

### [<![CDATA[Pharmaceutical Executive Daily: Rocket Pharmaceuticals Sells Pediatric Disease Priority Review Voucher]]>](https://longbridge.com/en/news/284627752.md)
*2026-04-29T18:33:50.000Z*
> Rocket Pharmaceuticals has sold its rare pediatric disease priority review voucher for $180 million, providing non-dilut

### [<![CDATA[Rocket Pharmaceuticals Enters $180 Definitive Agreement to Sell its Priority Review Voucher ]]>](https://longbridge.com/en/news/284586181.md)
*2026-04-29T13:20:29.000Z*
> Rocket Pharmaceuticals has sold its Priority Review Voucher (PRV) for $180 million, following the FDA's approval of Kres

### [Rocket to sell PRV for $180m to advance gene therapy pipeline](https://longbridge.com/en/news/284539876.md)
*2026-04-29T09:55:00.000Z*
> Rocket Pharmaceuticals plans to sell its Priority Review Voucher (PRV) for $180 million to fund its cardiovascular gene 

### [Rocket Pharmaceuticals Monetizes Voucher to Extend Cash Runway](https://longbridge.com/en/news/284380019.md)
*2026-04-28T11:58:21.000Z*
> Rocket Pharmaceuticals (RCKT) has sold a Rare Pediatric Disease Priority Review Voucher for $180 million, extending its